scholarly article | Q13442814 |
P356 | DOI | 10.1038/S41591-020-1082-2 |
P698 | PubMed publication ID | 33020648 |
P50 | author | Keith Flaherty | Q6384357 |
Dirk Schadendorf | Q32649390 | ||
Antoni Ribas | Q32649604 | ||
Reinhard Dummer | Q32650033 | ||
Caroline Robert | Q41784107 | ||
Georgina V. Long | Q42947998 | ||
Hussein Tawbi | Q89392894 | ||
Paolo Antonio Ascierto | Q89457677 | ||
P2093 | author name string | Celeste Lebbé | |
Mario Mandalà | |||
Victoria Atkinson | |||
Daniel Gusenleitner | |||
Erika Richtig | |||
Jan C Brase | |||
Ana Arance | |||
Naoya Yamazaki | |||
Catarina D Campbell | |||
Aisha Masood | |||
Paul D Nathan | |||
Eduard Gasal | |||
Neha Pakhle | |||
P2860 | cites work | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
Acquired and intrinsic resistance in cancer immunotherapy | Q26827701 | ||
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 | ||
A framework for variation discovery and genotyping using next-generation DNA sequencing data | Q29547262 | ||
HTSeq--a Python framework to work with high-throughput sequencing data | Q29614489 | ||
STAR: ultrafast universal RNA-seq aligner | Q29615052 | ||
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads | Q29617402 | ||
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
The Molecular Signatures Database (MSigDB) hallmark gene set collection | Q34509167 | ||
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 | ||
Molecular signatures database (MSigDB) 3.0. | Q35019708 | ||
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma | Q36612452 | ||
Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. | Q37695453 | ||
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma | Q39013253 | ||
Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. | Q39043132 | ||
PureCN: copy number calling and SNV classification using targeted short read sequencing. | Q39079807 | ||
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial | Q40182275 | ||
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. | Q40454933 | ||
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. | Q41950059 | ||
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. | Q45953253 | ||
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. | Q46394566 | ||
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. | Q47573421 | ||
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | Q47573472 | ||
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. | Q52681406 | ||
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. | Q52888037 | ||
Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. | Q54380273 | ||
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy | Q57472982 | ||
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma | Q64248097 | ||
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial | Q89481181 | ||
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | Q90342370 | ||
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 | Q90369153 | ||
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. | Q91013491 | ||
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors | Q91295682 | ||
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy | Q91503293 | ||
Immunological effects of BRAF+MEK inhibition | Q91523732 | ||
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study | Q92182785 | ||
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma | Q92415695 | ||
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients | Q92573076 | ||
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma | Q92573085 | ||
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma | Q92573091 | ||
P433 | issue | 10 | |
P921 | main subject | biomarker | Q864574 |
P304 | page(s) | 1557-1563 | |
P577 | publication date | 2020-10-05 | |
P1433 | published in | Nature Medicine | Q1633234 |
P1476 | title | Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i | |
P478 | volume | 26 |
Search more.